lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde
Univ Hosp Ulm, Germany.
Natl Ctr Sci Res Demokritos, Greece.
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences. Uppsala University, Sweden. (Linnaeus Ctr Biomat Chem, BMC;BBCL)ORCID iD: 0000-0001-7888-1571
Uppsala University, Sweden.
Show others and affiliations
2022 (English)In: Seminars in Immunology, ISSN 1044-5323, E-ISSN 1096-3618, Vol. 60, article id 101640Article, review/survey (Refereed) Published
Abstract [en]

Patients in the intensive care unit (ICU) often straddle the divide between life and death. Understanding the complex underlying pathomechanisms relevant to such situations may help intensivists select broadly acting treatment options that can improve the outcome for these patients. As one of the most important defense mechanisms of the innate immune system, the complement system plays a crucial role in a diverse spectrum of diseases that can necessitate ICU admission. Among others, myocardial infarction, acute lung injury/acute respiratory distress syndrome (ARDS), organ failure, and sepsis are characterized by an inadequate complement response, which can potentially be addressed via promising intervention options. Often, ICU monitoring and existing treatment options rely on massive intervention strategies to maintain the function of vital organs, and these approaches can further contribute to an unbalanced complement response. Artificial surfaces of extracorporeal organ support devices, transfusion of blood products, and the application of anticoagulants can all trigger or amplify undesired complement activation. It is, therefore, worth pursuing the evaluation of complement inhibition strategies in the setting of ICU treatment. Recently, clinical studies in COVID-19-related ARDS have shown promising effects of central inhibition at the level of C3 and paved the way for prospective investigation of this approach. In this review, we highlight the fundamental and often neglected role of complement in the ICU, with a special focus on targeted complement inhibition. We will also consider complement substitution therapies to temporarily counteract a disease/treatment-related complement consumption.

Place, publisher, year, edition, pages
Elsevier, 2022. Vol. 60, article id 101640
Keywords [en]
Complement system, C3 blockage, Intentive care unit
National Category
Immunology in the medical area
Research subject
Biomedical Sciences, Immunology
Identifiers
URN: urn:nbn:se:lnu:diva-118757DOI: 10.1016/j.smim.2022.101640ISI: 000901981000001PubMedID: 35853795Scopus ID: 2-s2.0-85134571519OAI: oai:DiVA.org:lnu-118757DiVA, id: diva2:1731327
Available from: 2023-01-26 Created: 2023-01-26 Last updated: 2023-02-21Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nilsson Ekdahl, Kristina

Search in DiVA

By author/editor
Nilsson Ekdahl, Kristina
By organisation
Department of Chemistry and Biomedical Sciences
In the same journal
Seminars in Immunology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 33 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf